Evidity Health Capital is a late-stage venture capital and growth equity firm focused on private medical technology companies, including medical devices, in vitro diagnostics, and disruptive digital health. Founded in 2014 as Canepa Healthcare, the firm invests in companies with commercialized products that have achieved U.S. regulatory clearance and need growth capital to scale. The firm rebranded to Evidity Health Capital in late 2019.
70% of their portfolio is in Healthcare. Their most common stage is series-d (50% of deals). Average disclosed round size is $62.0M (across 10 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series D
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 GT Medical Technologies | Series D | $53M | Jul 2025 |
| GT Medical Technologies | Series D | $37M | Jan 2025 |
 Augmedics | Series D | $82.5M | Jan 2023 |
| PPrelude Corporation (PreludeDx) | Growth | $20M | Mar 2022 |
 Magnolia Medical Technologies | Growth | $46M | Feb 2022 |
| AAkili, Inc. | Series D | $110.0M | May 2021 |
| AAkili, Inc. | Series D | $110M | Jan 2021 |
| CCardiva Medical, Inc. | Unknown | $45M | Jul 2020 |
| SSonde Health, Inc. | Series A | $16M | Apr 2019 |
| GT Medical Technologies | Series E | $100M | — |
Top Co-Investors
MedTech Venture Partners3 shared
Gilde Healthcare3 shared
M Ventures3 shared
VMG Partners2 shared
Accelmed Partners2 shared
New Leaf Venture Partners2 shared
QUAD Investment Management2 shared
Mirae Asset2 shared
Fearless Fund2 shared
Baillie Gifford2 shared
Neuberger Berman2 shared
Amgen Ventures2 shared
JAZZ Venture Partners2 shared
Polaris Partners2 shared
Lightspeed Venture Partners2 shared
SightLine Partners1 shared
RTW Investments, LP1 shared
HealthQuest Capital1 shared
Sectoral Asset Management1 shared
Last updated: 20 October 2026